Tetraph Pharma (TTPH) Misses Q2 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500, Nasdaq set for higher open as investors weigh weaker oil, PPI data
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Birkenstock surges on revenue beat, higher full-year outlook
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Tetraphase Pharmaceuticals (TTPH) Has Meaningful Catalysts Ahead, Baird Says
August 13, 2014 6:22 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $21 price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) saying they are incrementally more bullish following yesterday's earnings report.
In the release, Tetraphase provided updates to its pipeline mentioning that the eravacycline trials continue to... More
